Co-encapsulated nanoparticles of Erlotinib and Quercetin for targeting lung cancer through nuclear EGFR and PI3K/AKT inhibition

PD Ganthala, S Alavala, N Chella… - Colloids and Surfaces B …, 2022 - Elsevier
Erlotinib-based EGFR targeted therapy has proven significant clinical improvement against
non-small cell lung cancer (NSCLC). However, the anticancer activity of Erlotinib (Ertb) is …
被引用次数：37 相关文章

Co-encapsulated nanoparticles of Erlotinib and Quercetin for targeting lung cancer through nuclear EGFR and PI3K/AKT inhibition.

PD Ganthala, S Alavala, N Chella… - Colloids and surfaces …, 2021 - europepmc.org
Erlotinib-based EGFR targeted therapy has proven significant clinical improvement against
non-small cell lung cancer (NSCLC). However, the anticancer activity of Erlotinib (Ertb) is …

Co-encapsulated nanoparticles of Erlotinib and Quercetin for targeting lung cancer through nuclear EGFR and PI3K/AKT inhibition

PD Ganthala, S Alavala, N Chella… - … and surfaces. B …, 2022 - pubmed.ncbi.nlm.nih.gov
Erlotinib-based EGFR targeted therapy has proven significant clinical improvement against
non-small cell lung cancer (NSCLC). However, the anticancer activity of Erlotinib (Ertb) is …

[引用][C] Co-encapsulated nanoparticles of Erlotinib and Quercetin for targeting lung cancer through nuclear EGFR and PI3K/AKT inhibition

PD Ganthala, S Alavala, N Chella, SB Andugulapati… - 2022